Study of risk factors for the osteoporosis development in rheumatoid arthritis in real clinical practice

Introduction. Osteoporosis is a common complication of rheumatoid arthritis. Its development is associated with the mechanisms underlying in the progression of autoimmune inflammatory diseases and therapeutic approaches used for them. The study of risk factors for osteoporosis can contribute to the clarification of its pathogenesis components, as well as the development of new methods for prevention, diagnosis and treatment of this condition.

Aim. To study the role of anamnestic, clinical and laboratory factors for secondary osteoporosis in women with rheumatoid arthritis.

Materials and methods. 102 women with rheumatoid arthritis were enrolled in our study. Exclusion criterias were type 2 diabetes mellitus, hepatic cirrhosis, hepatocarcinoma and level of alanine aminotransferase ≥ than 3 upper limit ofnormal. The cumulative dose, duration and daily dose of glucocorticoids (GC) were determined by patient intake. All patients undergone standard clinical and immunological examination. Serum fetuin-A, 25-hydroxycalciferol, C-telopeptide of collagen I type, N-terminal propeptide of collagen I type levels were determined using ELISA. X-ray of afflicted joints and dual-energy x-ray absorptiometry were performed. Statistical analysis was performed using conventional methods. Forced data entry was used to perform multiple logistic regression. Hereinafter data is presented as odds ratio (OR) and 95% confirmation intervals (CI).

Results. OR for osteoporosis were higher in women of age ≥ 58.5 years (OR 1,07 (1.02–1.12)), body mass index (BMI) ≤ 27 kg/m2 (OR 1.1 (1.01–1.2)), cumulative dose of GC ≥ 7.6 g (OR 1.09 (1.02–1.17), serum fetuin-A levels ≤ 660 μg/ml (OR 1,05 (1,01–1,09) and if the duration of GC intake is more than 3 months (hereinafter if dose of glucocorticoids is ≥ 5 mg for prednisolone daily) (OR 12.3 (4.12–36.5). Adjusted OR for osteoporosis were higher in women of age ≥ 58.5 years old (adjOR 1.08 (1.01–1.16), serum fetuin-A levels ≤ 660 μg/ml (adjOR 1.08 (1.01–1.15) andif the duration of GC intake is ≥ than 3 months (adjOR 12.1 (1.44–102.3).

Conclusions. Women with RA of ≥ than 58.5 years old, duration of GCs intake more than 3 months and serum fetuin-A levels ≤ than 660 μg/ml had higher odds for osteoporosis.These are independent factors for osteoporosis in women with rheumatoid arthritis, whichshould be used in patient’s management.

1. Smolen J.S., Aletaha D., McInnes I.B. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038. https://doi.org/10.1016/s0140-6736(16)30173-8.

2. Hafez E.A., Mansour H.E., Hamza S.H., Moftah S.G., Younes T.B., Ismail M.A. Bone mineral density changes in patients with recent-onset rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2011;4:87–94. https://doi.org/10.4137/CMAMD.S7773.

3. Fardellone P., Salawati E., Le Monnier L., Goëb V. Bone Loss, Osteoporosis, and Fractures in Patients with Rheumatoid Arthritis: A Review. J Clin Med. 2020;9(10):3361. https://doi.org/10.3390/jcm9103361.

4. Adami G., Saag K.G. Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid Arthritis. Curr Rheumatol Rep. 2019;21(7):34. https://doi.org/10.1007/s11926-019-0836-7.

5. Heinlen L., Humphrey M.B. Skeletal complications of rheumatoid arthritis. Osteoporos Int. 2017;28(10):2801–2812. https://doi.org/10.1007/s00198-017-4170-5.

6. Wang Y., Zhao R., Gu Z., Dong C., Guo G., Li L. Effects of glucocorticoids on osteoporosis in rheumatoid arthritis: a systematic review and metaanalysis. Osteoporos Int. 2020;31(8):1401–1409. https://doi.org/10.1007/s00198-020-05360-w.

7. Hench P.S., Kendall E.C., Slocumb C.H., Polley H.F. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocortical hormone in arthritis: preliminary report. Ann Rheum Dis. 1949;8(2):97–104. https://doi.org/10.1136/ard.8.2.97.

8. Bollet A.J., Black R., Bunim J.J. Major undesirable side-effects resulting from prednisolone and prednisone. J Am Med Assoc. 1955;158(6):459–63. https://doi.org/10.1001/jama.1955.02960060017005.

9. Whittier X., Saag K.G. Glucocorticoid-induced Osteoporosis. Rheum Dis Clin North Am. 2016;42(1):177–189. https://doi.org/10.1016/j.rdc.2015.08.005.

10. Adler R.A., Hochberg M.C. Glucocorticoid-induced osteoporosis in men. J Endocrinol Invest. 2011;34(6):481–484. https://doi.org/10.1007/BF03346716.

11. Blavnsfeldt A.G., de Thurah A., Thomsen M. D, Tarp S., Langdahl B., Hauge E.M. The effect of glucocorticoids on bone mineral density in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomized, controlled trials. Bone. 2018;114:172–180. https://doi.org/10.1016/j.bone.2018.06.008.

12. Chotiyarnwong P., McCloskey E.V. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol. 2020;16(8):437–447. https://doi.org/10.1038/s41574-020-0341-0.

13. Von Scheven E., Corbin K.J., Stagi S., Cimaz R. Glucocorticoid-associated osteoporosis in chronic inflammatory diseases: epidemiology, mechanisms, diagnosis, and treatment. Curr Osteoporos Rep. 2014;12(3):289–299. https://doi.org/10.1007/s11914-014-0228-x.

14. Buckley L., Guyatt G., Fink H.A., Cannon M., Grossman J., Hansen K.E. et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–1537. https://doi.org/10.1002/art.40137.

15. Akhverdyan Yu.R., Zavodovsky B.V., Polyakova Yu.V., Sivordova L.E., Papichev E.V. The relationship between immunological and traditional markers of inflammation in patients with rheumatoid arthritis. Vyatskiy meditsinskiy vestnik = Vyatka Medical Bulletin. 2018;60(4):4–7. (In Russ.) Available at: https://vyatmedvestnik.ru/index.php/vmv/issue/view/30/no4_60_2018.

16. Binkert C., Demetriou M., Sukhu B., Szweras M., Tenenbaum H.C., Dennis J.W. Regulation of osteogenesis by fetuin. J Biol Chem. 1999;274(40):28514-28520. https://doi.org/10.1074/jbc.274.40.28514.

17. Heiss A., DuChesne A., Denecke B., Grötzinger J., Yamamoto K., Renné T., Jahnen-Dechent W. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem. 2003;278(15):13333-13341. https://doi.org/10.1074/jbc.M210868200.

18. Dasgupta S., Bhattacharya S., Biswas A., Majumdar S.S., Mukhopadhyay S., Ray S., Bhattacharya S. NF-kappaB mediates lipid-induced fetuin-A expression in hepatocytes that impairs adipocyte function effecting insulin resistance. Biochem J. 2010;429(3):451–462. https://doi.org/10.1042/BJ20100330.

19. Herrmann M., Kinkeldey A., Jahnen-Dechent W. Fetuin-A function in systemic mineral metabolism. Trends Cardiovasc Med. 2012;22(8):197–201. https://doi.org/10.1016/j.tcm.2012.07.020.

20. Özkan E., Özkan H., Bilgiç S., Odabaşi E., Can N., Akgül E.Ö. et al. Serum fetuin-A levels in postmenopausal women with osteoporosis. Turk J Med Sci. 2014;44(6):985–988. https://doi.org/10.3906/sag-1308-28.

21. Sari A., Uslu T. The relationship between fetuin-A and bone mineral density in postmenopausal osteoporosis. Turk J Med Sci. 2013;28(3):195–201. https://doi.org/10.5606/tjr.2013.2468.

22. Dydykina I.S., Alekseeva L.I. Osteoporosis in rheumatoid arthritis: diagnosis, risk factors, fractures, treatment. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2011;49(5):13–17. (In Russ.) Available at: https://rsp.mediar-press.net/rsp/article/view/1286.

23. Podvorotova M.M., Dydykina I.S., Taskina E.A., Raskina T.A., Koroleva M.A., Muradyants A.A. et al. Risk factors for fractures in patients with rheumatoid arthritis (preliminary results of the multicenter program “Osteoporosis in rheumatoid arthritis: Diagnosis, risk factors, fractures, treatment”). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(2):154–158. (In Russ.) Available at: https://rsp.mediar-press.net/rsp/article/view/781.

24. Oray M., Abu Samra K., Ebrahimiadib N., Meese H., Foster C.S. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457–465. https://doi.org/10.1517/14740338.2016.1140743.

25. Van de Vlekkert J., Hoogendijk J.E., de Haan R.J., Algra A., van der Tweel I., van der Pol W.L. et al. Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord. 2010;20(6):382–389. https://doi.org/10.1016/j.nmd.2010.03.011.

26. De Wit M.P., Smolen J.S., Gossec L., van der Heijde D.M. Treating rheumatoid arthritis to target: the patient version of the international recommendations. Ann Rheum Dis. 2011;70(6):891–895. https://doi.org/10.1136/ard.2010.146662.

27. Smolen J.S., Breedveld F.C., Burmester G.R., Bykerk V., Dougados M., Emery P. et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15. https://doi.org/10.1136/annrheumdis-2015-207524.

28. Nasonov E.L. Pharmacotherapy for rheumatoid arthritis: Russian and international guidelines. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2016;54(5):557–571. (In Russ.) Available at: https://rsp.mediar-press.net/rsp/article/view/2302.

29. Bourebaba L., Marycz K. Pathophysiological Implication of Fetuin-A Glycoprotein in the Development of Metabolic Disorders: A Concise Review. J Clin Med. 2019;8(12):2033. https://doi.org/10.3390/jcm8122033.

30. Price P.A., Toroian D., Lim J.E. Mineralization by inhibitor exclusion: the calcification of collagen with fetuin. J Biol Chem. 2009;284(25):17092-17101. https://doi.org/10.1074/jbc.M109.007013.

31. Wang H., Sama A.E. Anti-inflammatory role of fetuin-A in injury and infection. Curr Mol Med. 2012;12(5):625–633. https://doi.org/10.2174/156652412800620039.